FIGURE

Fig. 9

ID

ZDB-FIG-220719-69

Publication

B�r et al., 2022 - Chimeric HDAC and the cytoskeleton inhibitor broxbam as a novel therapeutic strategy for liver cancer

Other Figures

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13

All Figure Page

Back to All Figure Page

Fig. 9

Responses of the cytoskeleton in HepG2 cells to bb treatment. Confocal immunofluorescence images 24 h after incubation with bb (0.6 �M) or vs. (4 �M). ?-Tubulin (red), f-actin (green) and DAPI-stained nuclei (blue) staining are shown. Scale bar, 30 �m. Ctrl, control; bb, broxbam; vs, vorinostat. Images are representative of n=3 independent experiments.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Int. J. Oncol.